Eton Pharmaceuticals, Inc.
ETON · Nasdaq · United States
Share price · ETON
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ETON's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+19.7%
- Day beforeOther material event
- 30 Sep 2026-13.0%
Nothing announced by ETON that day or the session before.
- 14 Aug 2026+44.3%
- 28 Jul 2026+10.3%
Nothing announced by ETON that day or the session before.
- 17 Jul 2026+13.8%
Nothing announced by ETON that day or the session before.
- 18 May 2026+7.4%
Nothing announced by ETON that day or the session before.
- 1 May 2026+19.8%
Nothing announced by ETON that day or the session before.
- 16 Apr 2026-9.4%
Nothing announced by ETON that day or the session before.
- 20 Mar 2026+7.5%
Nothing announced by ETON that day or the session before.
- 19 Mar 2026+9.2%
Nothing announced by ETON that day or the session before.
Share of unusual movement by asset
For each asset, the share of ETON's own-move activity since 27 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Diazepam (Libervant) (Libervant)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 42% |
| Sessions with no dated event | — | 58% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GABA-A receptorSmall molecule | Epilepsy |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $58M | $5.3M | $56M | —$35M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $38M | $1.0M | $27M | —$7.3M operating cash flow | report ↗ |
| 2026-Q1 | $24M | $1.9M | $20M | —$7.4M operating cash flow | report ↗ |
| 2025-Q3 | $22M | $1.1M | $37M | $1.9M$12M operating cash flow | report ↗ |
| 2025-Q2 | $19M | $3.7M | $25M | $2.6M$8.0M operating cash flow | report ↗ |
| 2025-Q1 | $17M | $1.2M | $17M | $1.6M$2.1M operating cash flow | report ↗ |
| 2024-Q3 | $10M | $0.5M | $20M | —$3.0M operating cash flow | report ↗ |
| 2024-Q2 | $9.1M | $3.0M | $18M | $3.0M$1.3M operating cash flow | report ↗ |
| 2024-Q1 | $8.0M | $0.7M | $17M | $0.8M-$2.5M operating cash flow | report ↗ |
| 2023-Q3 | $7.0M | $0.6M | $22M | $0.6M$0.9M operating cash flow | report ↗ |
| 2023-Q2 | $12M | $1.1M | $22M | —$7.1M operating cash flow | report ↗ |
| 2023-Q1 | $5.3M | $0.5M | $15M | $2.7M-$1.6M operating cash flow | report ↗ |
| 2022-Q3 | $3.2M | $0.7M | $13M | $3.0M-$1.7M operating cash flow | report ↗ |
| 2022-Q2 | $7.4M | $0.7M | $17M | $1.6M$2.5M operating cash flow | report ↗ |
| 2022-Q1 | $2.2M | $1.6M | $15M | $5.3M$1.2M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $80M | $7.8M | $26M | $1.1M$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 36 sales ($35.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Erdogan-Trinkaus Ipek · Chief Commercial Officer | Option exercise | 3,500 | $15.47 | $54K | Form 4 |
| 2026-11-10 | Erdogan-Trinkaus Ipek · Chief Commercial Officer | Open-market sale | 2,340 | $67.18 | $157K | Form 4 |
| 2026-11-10 | Erdogan-Trinkaus Ipek · Chief Commercial Officer | Open-market sale | 1,160 | $67.88 | $79K | Form 4 |
| 2026-11-10 | Erdogan-Trinkaus Ipek · Chief Commercial Officer | Option exercise (derivative) | 3,500 | — | — | Form 4 |
| 2026-11-10 | CASAMENTO CHARLES J · director | Option exercise | 12,500 | $7.31 | $91K | Form 4 |
| 2026-11-10 | CASAMENTO CHARLES J · director | Option exercise | 27,400 | $3.58 | $98K | Form 4 |
| 2026-11-10 | CASAMENTO CHARLES J · director | Option exercise | 19,655 | $8.61 | $169K | Form 4 |
| 2026-11-10 | CASAMENTO CHARLES J · director | Option exercise | 21,000 | $3.78 | $79K | Form 4 |